|
PEX1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62503344114384E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.43689570931383E-15 |
| Normal-vs-Stage2 |
3.50719999999693E-05 |
| Normal-vs-Stage3 |
2.89435142519778E-13 |
| Normal-vs-Stage4 |
1.6521228829447E-12 |
| Stage1-vs-Stage2 |
1.223440E-01 |
| Stage1-vs-Stage3 |
4.666500E-02 |
| Stage1-vs-Stage4 |
1.793640E-02 |
| Stage2-vs-Stage3 |
1.669990E-02 |
| Stage2-vs-Stage4 |
5.163000E-03 |
| Stage3-vs-Stage4 |
4.885000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.96617000000066E-05 |
| Normal-vs-Asian |
7.87100384869177E-11 |
| Caucasian-vs-AfricanAmerican |
3.330400E-01 |
| Caucasian-vs-Asian |
9.380400E-01 |
| AfricanAmerican-vs-Asian |
3.495000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.48436818392383E-13 |
| Normal-vs-Female |
1.63236091310637E-12 |
| Male-vs-Female |
6.662800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.68043357007264E-12 |
| Normal-vs-Age(41-60Yrs) |
1.10911280160053E-13 |
| Normal-vs-Age(61-80Yrs) |
2.47959985877344E-10 |
| Normal-vs-Age(81-100Yrs) |
5.56480000000192E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.536600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.487800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.616800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.999800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.038400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.504600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.398900E-04 |
| Classical-VS-Follicular |
8.300400E-03 |
| Classical-VS-Other |
6.945600E-01 |
| Classical-VS-Normal |
1.62470037423645E-12 |
| Tall-VS-Follicular |
2.02159999995732E-06 |
| Tall-VS-Other |
2.110400E-01 |
| Tall-VS-Normal |
2.33146835171283E-15 |
| Follicular-VS-Other |
2.611000E-01 |
| Follicular-VS-Normal |
2.41369999999241E-05 |
| Other-VS-Normal |
4.995900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.2245986143239E-11 |
| Normal-vs-N1 |
1.46771483855446E-13 |
| N0-vs-N1 |
3.074200E-02 |
|
|
